Saroglitazar

Drug Profile

Saroglitazar

Alternative Names: Lipaglyn; Saroglitazar Magnesium; Saroglitazar Mg; ZY-H1

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zydus-Cadila
  • Developer Zydus Cadila
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertriglyceridaemia
  • Phase III Lipodystrophy; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Phase II Primary biliary cirrhosis
  • Clinical Phase Unknown Non-alcoholic fatty liver disease

Most Recent Events

  • 12 Apr 2017 Zydus Discovery DMCC plans a phase II trial in Primary biliary cirrhosis in USA (PO) (NCT03112681)
  • 06 Apr 2017 Phase-II clinical trials in Hypertriglyceridaemia in USA (PO) (NCT03097107)
  • 03 Apr 2017 Zydus plans a phase II trial for Hypertriglyceridaemia in USA (NCT03097107)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top